IMPORTANCE: A significant portion of frontotemporal lobar degeneration (FTLD) is due to inherited gene mutations, and we are unaware of a large sequential series that includes a recently discovered inherited cause of FTLD. There is also great need to develop clinical tools and approaches that will assist clinicians in the identification and counseling of patients with FTLD and their families regarding the likelihood of an identifiable genetic cause. OBJECTIVES: To ascertain the frequency of inherited FTLD and develop validated pedigree classification criteria for FTLD that provide a standardized means to evaluate pedigree information and insight into the likelihood of mutation-positive genetic test results for C9orf72, MAPT, and GRN. DESIGN: Information about pedigrees and DNA was collected from 306 serially assessed patients with a clinical diagnosis of FTLD. This information included gene test results for C9orf72, MAPT, and GRN. Pedigree classification criteria were developed based on a literature review of FTLD genetics and pedigree tools and then refined by reviewing mutation-positive and -negative pedigrees to determine differentiating characteristics. SETTING: Academic medical center. PARTICIPANTS: Patients with FTLD. MAIN OUTCOMES AND MEASURES: Familial risk. RESULTS: The rate of C9orf72, MAPT, or GRN mutation-positive FTLD in this series was 15.4%. Categories designating the risk level for hereditary cause were termed high, medium, low, apparent sporadic, and unknown significance. Thirty-nine pedigrees (12.7%) met criteria for high, 31 (10.1%) for medium, 46 (15.0%) for low, 91 (29.7%) for apparent sporadic, and 99 (32.4%) for unknown significance. The mutation-detection rates were as follows: high, 64.1%; medium, 29%; low, 10.9%; apparent sporadic, 1.1%; and unknown significance, 7.1%. Mutation-detection rates differed significantly between the high and other categories. CONCLUSIONS AND RELEVANCE: Mutation rates are high in FTLD spectrum disorders, and the proposed criteria provide a validated standard for the classification of FTLD pedigrees. The combination of pedigree criteria and mutation-detection rates has important implications for genetic counseling and testing in clinical settings.
IMPORTANCE: A significant portion of frontotemporal lobar degeneration (FTLD) is due to inherited gene mutations, and we are unaware of a large sequential series that includes a recently discovered inherited cause of FTLD. There is also great need to develop clinical tools and approaches that will assist clinicians in the identification and counseling of patients with FTLD and their families regarding the likelihood of an identifiable genetic cause. OBJECTIVES: To ascertain the frequency of inherited FTLD and develop validated pedigree classification criteria for FTLD that provide a standardized means to evaluate pedigree information and insight into the likelihood of mutation-positive genetic test results for C9orf72, MAPT, and GRN. DESIGN: Information about pedigrees and DNA was collected from 306 serially assessed patients with a clinical diagnosis of FTLD. This information included gene test results for C9orf72, MAPT, and GRN. Pedigree classification criteria were developed based on a literature review of FTLD genetics and pedigree tools and then refined by reviewing mutation-positive and -negative pedigrees to determine differentiating characteristics. SETTING: Academic medical center. PARTICIPANTS: Patients with FTLD. MAIN OUTCOMES AND MEASURES: Familial risk. RESULTS: The rate of C9orf72, MAPT, or GRN mutation-positive FTLD in this series was 15.4%. Categories designating the risk level for hereditary cause were termed high, medium, low, apparent sporadic, and unknown significance. Thirty-nine pedigrees (12.7%) met criteria for high, 31 (10.1%) for medium, 46 (15.0%) for low, 91 (29.7%) for apparent sporadic, and 99 (32.4%) for unknown significance. The mutation-detection rates were as follows: high, 64.1%; medium, 29%; low, 10.9%; apparent sporadic, 1.1%; and unknown significance, 7.1%. Mutation-detection rates differed significantly between the high and other categories. CONCLUSIONS AND RELEVANCE: Mutation rates are high in FTLD spectrum disorders, and the proposed criteria provide a validated standard for the classification of FTLD pedigrees. The combination of pedigree criteria and mutation-detection rates has important implications for genetic counseling and testing in clinical settings.
Authors: Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers Journal: Neuron Date: 2011-09-21 Impact factor: 17.173
Authors: M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman Journal: Neurology Date: 2011-02-16 Impact factor: 9.910
Authors: Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin Journal: Arch Neurol Date: 2010-02
Authors: T Van Langenhove; J van der Zee; K Sleegers; S Engelborghs; R Vandenberghe; I Gijselinck; M Van den Broeck; M Mattheijssens; K Peeters; P P De Deyn; M Cruts; C Van Broeckhoven Journal: Neurology Date: 2010-02-02 Impact factor: 9.910
Authors: B Borroni; C Bonvicini; A Alberici; E Buratti; C Agosti; S Archetti; A Papetti; C Stuani; M Di Luca; M Gennarelli; A Padovani Journal: Hum Mutat Date: 2009-11 Impact factor: 4.878
Authors: Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller Journal: Brain Date: 2011-08-02 Impact factor: 13.501
Authors: Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor Journal: Neuron Date: 2011-09-21 Impact factor: 17.173
Authors: Colin J Mahoney; Jon Beck; Jonathan D Rohrer; Tammaryn Lashley; Kin Mok; Tim Shakespeare; Tom Yeatman; Elizabeth K Warrington; Jonathan M Schott; Nick C Fox; Martin N Rossor; John Hardy; John Collinge; Tamas Revesz; Simon Mead; Jason D Warren Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Kieren Po; Felicity V C Leslie; Natalie Gracia; Lauren Bartley; John B J Kwok; Glenda M Halliday; John R Hodges; James R Burrell Journal: J Neurol Date: 2014-08-26 Impact factor: 4.849
Authors: David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: Ann Neurol Date: 2017-08-19 Impact factor: 10.422
Authors: Corey T McMillan; Jon B Toledo; Brian B Avants; Philip A Cook; Elisabeth M Wood; Eunran Suh; David J Irwin; John Powers; Christopher Olm; Lauren Elman; Leo McCluskey; Gerard D Schellenberg; Virginia M-Y Lee; John Q Trojanowski; Vivianna M Van Deerlin; Murray Grossman Journal: Neurobiol Aging Date: 2013-12-02 Impact factor: 4.673
Authors: Lucia A A Giannini; Sharon X Xie; Corey T McMillan; Mendy Liang; Andrew Williams; Charles Jester; Katya Rascovsky; David A Wolk; Sharon Ash; Edward B Lee; John Q Trojanowski; Murray Grossman; David J Irwin Journal: Ann Neurol Date: 2019-03-28 Impact factor: 10.422
Authors: Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan Journal: Neurobiol Aging Date: 2018-04-17 Impact factor: 4.673
Authors: Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302
Authors: David J Irwin; Corey T McMillan; EunRan Suh; John Powers; Katya Rascovsky; Elisabeth M Wood; Jon B Toledo; Steven E Arnold; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Murray Grossman Journal: Neurology Date: 2014-07-03 Impact factor: 9.910